Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
I know, that buy dildos online is cheaper.
Popular Articles

First International Conference On Cancer Of Unknown Primary To Be Held London October 15
When a patient is diagnosed with metastatic disease the primary site of the cancer is usually, but not always, evident. When the origin of the cancer is not identified it is described as a Cancer of Unknown Primary site, or CUP.
drugs without prescription
Scientists Follow Live Infection By Food-poisoning Bacteria Listeria
Scientists in Portugal and France managed to follow the patterns of gene expression in food-poisoning bacteria Listeria monocytogenes (L. monocytogenes) live during infection for the first time. The work about to be published in PLoS Pathogens shows how the bacterial genome shifts to better adapt to infection by activating genes involved in virulence and subversion of the host defences, as well as adaptation to the host conditions. This is the first time that the molecular interactions between L. monocytogenes and its host, as they occur during the different steps of infection, are followed in real time paving the way, not only to the development of new therapies against this potentially lethal bacterium, but also for the study of other pathogen/host interactions.
News of the day
Fewer Americans Following Healthy Lifestyle
A new study found that compared with two decades ago, fewer Americans are following a healthy lifestyle. This is despite the mounting evidence
Mental Health

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar"s internal research program. The first patient enrolled in the trial has already started treatment with the compound. PM1183 is a new synthetic alkaloid which binds to the minor groove of DNA, generates DNA double strand breaks and caused cell cycle perturbation that finally results in a specific type of cell death calles apoptosis. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventional alkylating agents. In preclinical studies PM1183 demonstrated strong in vitro and in vivo antitumoural activity in a wide variety of tumour cell lines and human transplantable xenografted tumours. PM11883 also demonstrated a manageable and reversible preclinical toxicology profile. As a single agent, PM1183 significantly reduced tumor proliferation in vivo, with the strongest effect observed on the xenografts of the breast cancer cell line MX1. PM1183 was also evaluated for in vivo activity using M5076 sarcoma model that spontaneously metastasizes in the liver of the C57Bl/6 female tumor bearing mice. The compound statistically reduced the number of liver metastasis compared to placebo-treated animal. In vitro studies show cell lines with mutant p53 or lacking P53 are more sensitive with PM1183. Further studies are on going in human ovarian cancer and human sarcoma xenografts. PharmaMar"s clinical portfolio currently includes five new, first-in-class compounds: Yondelis®, Aplidin®, Zalypsis®, Irvalec® and PM1183. The PharmaMar patent portfolio is composed of over 1,800 files and it has a continous flow of new compound into the clinic (1 new compound every 24 months). About PM1183 PM1183 is a new synthetic alkaloid compound developed by PharmaMar"s internal research program. It binds to the minor groove of DNA, generates DNA double strand brakes and caused cell cycle perturpation mainly consisting in a delayed progression of S phase and cycle arrest in G2M. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventionaol alkylating agents. PharmaMar PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar"s first product, Yondelis®, received marketing authorisation from the European Commission for the treatment of advanced or metastatic soft tissue sarcoma in September 2007. In 2008 a registration dossier was submitted to the European Medicines Agency (EMEA) and Food and Drug Administration (FDA, USA) for Yondelis® when administered in combination with DOXIL®/Caelyx™ (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer. It is also in phase II clinical trials for prostate, breast, and lung cancers. Three other PharmaMar compounds, Aplidin®, Irvalec®, and Zalypsis® are in various stages of clinical development. PharmaMar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009